Dimerix (ASX:DXB) is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix’ lead clinical asset, DMX-200 (or QYTOVRA® in some territories), is in Phase 3 trials as a treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease.
Looking for a particular Dimerix Limited employee's phone or email?
Dimerix Limited Questions
The Dimerix Limited annual revenue was $644000 in 2026.
Nina Webster is the CEO and Managing Director of Dimerix Limited.
13 people are employed at Dimerix Limited.
Dimerix Limited is based in Melbourne, Victoria.
The NAICS codes for Dimerix Limited are [3254, 541, 32, 54, 32541, 325].
The SIC codes for Dimerix Limited are [28, 283].
Top Dimerix Limited Employees
-
Nina Webster
CEO and Managing Director at Dimerix Limited
Melbourne, VIC, AU2 -
Robert Shepherd
Chief Commercialisation Officer (CCO) at Dimerix Limited
Melbourne, VIC, AU21 -
David Fuller
Chief Medical Officer at Dimerix Limited
Sydney, NSW, AU11 -
Alisha Smith
Clinical Operations Director at Dimerix Limited
Melbourne, VIC, AU21 -
Natalija Gak
Commercial Operations Director at Dimerix Limited
Melbourne, VIC, AU11 -
Mark Diamond
Non Executive Chair at Dimerix Limited
Melbourne, VIC, AU43 -
Inus van Rensburg
Associate Director, Product Development at Dimerix Limited
Mount Eliza, VIC, AU2 -
2
-
Mrinal Murali
Clinical Project Manager at Dimerix Limited
Melbourne, VIC, AU12 -
Preetam Ghogale
Product Development Manager at Dimerix Limited
Melbourne, VIC, AU31
Related Companies
